Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | PSMB1 | P20618 | 5/20 | 0.53 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.53 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | CACNA1F | O60840 | 3/20 | 0.50 |
| ▸ | BCHE | P06276 | 3/20 | 0.50 |
| ▸ | CACNA1D | Q01668 | 3/20 | 0.50 |
| ▸ | CACNA1S | Q13698 | 3/20 | 0.50 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2741686 | 0.83 | PSMB1 (0.59) | KDM4EHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL223800 | 0.82 | KCNH2 (0.81) | KDM4EHRH3KCNH2PSMB1PSMB5 | |
| SCHEMBL228881 | 0.82 | KCNH2 (0.81) | KDM4EHRH3KCNH2PSMB1PSMB5 | |
| SCHEMBL30969265 | 0.82 | PSMB1 (0.58) | KDM4EHRH3KCNH2PSMB1PSMB5 | |
| SCHEMBL226984 | 0.81 | PSMB1 (0.57) | KDM4EHRH3KCNH2PSMB1PSMB5 | |
| Hydrochloric Acid SCHEMBL8404070 | 0.81 | KCNH2 (0.80) | KDM4EHRH3KCNH2PSMB1PSMB5 | |
| SCHEMBL21408538 | 0.81 | HRH3 (0.79) | KDM4EHRH3KCNH2PSMB1PSMB5 | |
| SCHEMBL9901416 | 0.78 | CYP1A2 (0.51) | KDM4EALDH1A1 | |
| SCHEMBL749735 | 0.78 | CYP1A2 (0.45) | KDM4EALDH1A1 | |
| SCHEMBL7536311 | 0.77 | CYP1A2 (0.54) | KDM4EHRH3KCNH2CACNA1FCACNA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ESR1, GPER1, ESR2 | KDM4E 708/4885HRH3 561/4885KCNH2 1700/4885 |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | BRCA1, BCR, RCC1 | KDM4E 577/4885HRH3 114/4885KCNH2 1014/4885 |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | KDM4E 718/4885HRH3 583/4885KCNH2 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.